Dysbindin C-A-T haplotype is associated with thicker medial orbitofrontal cortex in healthy population

NeuroImage

Volumn 55, Issue 2, 2011, Pages 508-513

  Cerasa, Antonio ^a   Quattrone, Aldo ^a,b   Gioia, Maria C ^a,c   Tarantino, Patrizia ^a   Annesi, Grazia ^a   Assogna, Francesca ^d   Caltagirone, Carlo ^d,e   De Luca, Vincenzo ^f   Spalletta, Gianfranco ^d  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^c UNIVERSITY OF CALABRIA   (Italy)

^d IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

C A T dysbindin haplotype; Cortical thickness; Imaging genetics; Medial orbitofrontal cortex

Indexed keywords

ADULT; AGED; ARTICLE; BRAIN CORTEX THICKNESS; CONTROLLED STUDY; DYSBINDIN GENE; FEMALE; GENE; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NORMAL HUMAN; ORBITAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; CARRIER PROTEINS; CEREBRAL CORTEX; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79551599177     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2010.12.042     Document Type: Article

References (60)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995, 52:258-266.
2. Bray N.J., Preece A., Williams N.M., Moskvina V., Buckland P.R., Owen M.J., O'Donovan M.C. Haplotypes at the dystrobrevin binding protein 1 (DTNBP1) gene locus mediate risk for schizophrenia through reduced DTNBP1 expression. Hum. Mol. Genet. 2005, 14:1947-1954.
3. Burdick K., Lencz T., Funke B., Finn C., Szeszko P., Kane J.M., Kucherlapati R., Malhotra A.K. Genetic variation in DTNBP1 influences general cognitive ability. Hum. Mol. Genet. 2006, 15:1563-1568.
4. Carlesimo G.A., Caltagirone C., Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery. Eur. Neurol. 1996, 36:378-384.
5. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1998, Lawrence Earlbaum Associates, Hillsdale, NJ. 2nd ed.
6. Dale A.M., Fischl B., Sereno M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999, 9:179-194.
7. Davidson L.L., Heinrichs R.W. Quantification of frontal and temporal lobe brain-imaging findings in schizophrenia: a metaanalysis. Psychiatry Res. 2003, 122:69-87.
8. Deichmann R., Schwarzbauer C., Turner R. Optimisation of the 3D MDEFT sequence for anatomical brain imaging: technical implications at 1.5 and 3 T. Neuroimage 2004, 21:757-767.
9. Donohoe G., Morris D., De Sanctis P., Magno E., Montesi J., Garavan H.P., Robertson I.H., Javitt D.C., Gill M., Corvin A.P., Foxe J.J. Early visual processing deficits in dysbindin-associated schizophrenia. Biol. Psychiatry 2008, 63:484-489.
10. Donohoe G., Morris D., Clarke S., McGhee K., Schwaiger S., Nangle J.M., Garavan H., Robertson I.H., Gill M., Corvin A. Variance in neurocognitive performance is associated with dysbindin-1 in schizophrenia: a preliminary study. Neuropsychologia 2007, 45:454-458.
11. Donohoe G., Frodl T., Morris D., Spoletini I., Cannon D.M., Cherubini A., Caltagirone C., Bossù P., McDonald C., Gill M., Corvin A.P., Spalletta G. Reduced occipital and prefrontal brain volumes in dysbindin-associated schizophrenia. Neuropsychopharmacology 2010, 35:368-373.
12. Fallgatter A.J., Herrmann M., Hohoff C., Ehlis A., Jarczok T., Freitag C.M., Deckert J. DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in healthy individuals. Neuropsychopharmacology 2006, 31:2002-2010.
13. Fallgatter A.J., Ehlis A., Herrmann M., Hohoff C., Reif A., Freitag C., Deckert J. DTNBP1 (dysbindin) gene variants modulate prefrontal brain function in schizophrenic patients-support for the glutamate hypothesis of schizophrenias. Genes Brain Behav. 2010, 9:489-497.
14. Feng L., Wang C.Y., Jiang H., Oho C., Mizuno K., Dugich-Djordjevic M., Lu B. Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons. Brain Res. Mol. Brain Res. 1999, 66:62-70.
15. First M.B., Gibbon M., Spitzer R.L., Williams J.B.W., Benjamin L.S. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II): Clinician Version 1997, American Psychiatric Press, Washington.
16. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I): Clinician Version 1997, American Psychiatric Press, Washington.
17. Fischl B., Dale A.M. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl Acad. Sci. USA 2000, 97:11050-11055.
18. Fischl B., Sereno M.I., Dale A.M. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. Neuroimage 1999, 9:195-207.
19. Folstein M.F., Folstein S.E., McHugh P.R. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12:189-198.
20. Funke B., Finn C.T., Plocik A.M., Lake S., DeRosse P., Kane J.M., et al. Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am. J. Hum. Genet. 2004, 75:891-898.
21. Guo A.Y., Sun J., Riley B.P., Thiselton D.L., Kendler K.S., Zhao Z. The dystrobrevin-binding protein 1 gene: features and networks. Mol. Psychiatry 2009, 14:18-29.
22. Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959, 32:50-55.
23. Hamilton H. Development of a rating scale for primary depressive illness. Br. J. Soc. Clin. Psychol. 1967, 6:278-296.
24. Hashimoto T., Lewis D.A. BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Am. J. Psychiatry 2006, 163:534-537.
25. Heaton R.K., Chelune G.J., Talley J.L., Kay G.C., Curtiss G. Wisconsin Card Sorting Test Manual 1993, Psychological Assessment Resources, Odessa, FL.
26. Ho B.C., Andreasen N.C., Dawson J.D., Wassink T.H. Association between brain-derived neurotrophic factor Val66Met gene polymorphism and progressive brain volume changes in schizophrenia. Am. J. Psychiatry 2007, 164:1890-1899.
27. Kalkman H. The role of the phosphatidylinositide 3-kinase protein kinase B pathway in schizophrenia. Pharmacol. Ther. 2006, 110:117-134.
28. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmuller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 1980, 20:379-382.
29. Kirov G., Ivanov D., Williams N.M., Preece A., Nikolov I., Milev R., et al. Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria. Biol. Psychiatry 2004, 55:971-975.
30. Markov V., Krug A., Krach S., Whitney C., Eggermann T., Zerres K., et al. Genetic variation in schizophrenia-risk-gene dysbindin 1 modulates brain activation in anterior cingulate cortex and right temporal gyrus during language production in healthy individuals. Neuroimage 2009, 47:2016-2022.
31. Markov V., Krug A., Krach S., Jansen A., Eggermann T., Zerres K., et al. Impact of schizophrenia-risk gene dysbindin 1 on brain activation in bilateral middle frontal gyrus during a working memory task in healthy individuals. Hum. Brain Mapp. 2010, 31:266-275.
32. Mattay V., Goldberg T.E., Sambataro F., Weinberger D.R. Brain longevity and normal cognitive aging: insights from imaging genetics. Biol. Psychol. 2008, 79:9-22.
33. Mechelli A., Viding E., Kumar A., Pettersson-Yeo W., Fusar-Poli P., Tognin S., et al. Dysbindin modulates brain function during visual processing in children. Neuroimage 2010, 49:817-822.
34. Moghaddam B., Krystal J.H. The neurochemistry of schizophrenia. Schizophrenia 2003, 349-364. Blackwell Science, Oxford. 2nd edn. S.J. Hirsch, D.R. Weinberger (Eds.).
35. Moghaddam B., Homayoun H. Divergent plasticity of prefrontal cortex networks. Neuropsychopharmacology 2008, 33:42-55.
36. Mutsuddi M., Morris D.W., Waggoner S.G., Daly M.J., Scolnick E.M., Sklar P. Analysis of high-resolution HapMap of DTNBP1 (dysbindin) suggests no consistency between reported common variant associations and schizophrenia. Am. J. Hum. Genet. 2006, 79:903-909.
37. Nesvåg R., Lawyer G., Varnäs K., Fjell A.M., Walhovd K.B., Frigessi A.J., et al. Regional thinning of the cerebral cortex in schizophrenia: effects of diagnosis, age and antipsychotic medication. Schizophr. Res. 2008, 98:16-28.
38. Narr K.L., Szeszko P.R., Lencz T., Woods R.P., Hamilton L.S., Phillips O., et al. DTNBP1 is associated with imaging phenotypes in schizophrenia. Hum. Brain Mapp. 2009, 30:3783-3794.
39. Numakawa T., Yagasaki Y., Ishimoto T., Okada T., Suzuki T., Iwata N., et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum. Mol. Genet. 2004, 13:2699-2708.
40. Oldfield R.C. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia 1971, 9:97-113.
41. Petersen R.C., Smith G.E., Waring S.C., Ivnik R.J., Tangalos E.G., Kokmen E. Mild cognitive impairment. Clinical characterization and outcome. Arch. Neurol. 1999, 56:303-308.
42. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry 2005, 10:434-449.
43. Schwab S.G., Knapp M., Mondabon S., Hallmayer J., Borrmann-Hassenbach M., et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 2003, 72:185-190.
44. Spalletta G., Morris D.W., Angelucci F., Rubino I.A., Spoletini I., Bria P., et al. BDNF Val66Met polymorphism is associated with aggressive behavior in schizophrenia. Eur. Psychiatry 2010, 25:311-313.
45. Spoletini I., Cherubini A., Di Paola M., Banfi G., Rüsch N., Martinotti G., et al. Reduced fronto-temporal connectivity is associated with frontal grey matter density reduction and neuropsychological deficit in schizophrenia. Schizophr. Res. 2009, 108:57-68.
46. Stephens M., Smith N.J., Donnelly P. A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 2001, 68:978-989.
47. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am. J. Hum. Genet. 2002, 71:337-348.
48. Stroop J.R. Studies of interference in serial verbal reactions. J. Exp. Psychol. 1935, 18:643-662.
49. Sudhof T.C. The synaptic vesicle cycle: a cascade of protein-protein interactions. Nature 1995, 375:645-653.
50. Takei N., Sasaoka K., Inoue K., Takahashi M., Endo Y., Hatanaka H. Brain-derived neurotrophic factor increases the stimulation evoked release of glutamate and the levels of exocytosis-associated proteins in cultured cortical neurons from embryonic rats. J. Neurochem. 1997, 68:370-375.
51. Talbot K., Cho D., Ong W., Benson M., Han L., Kazi H., et al. Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. Hum. Mol. Genet. 2006, 15:3041-3054.
52. Talbot K., Eidem W.L., Tinsley C.L., Benson M.A., Thompson E.W., Smith R.J., et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J. Clin. Invest. 2004, 113:1353-1363.
53. van den Oord E.J., Sullivan P.F., Jiang Y., Walsh D., O'Neill F.A., Kendler K.S., Riley B.P. Identification of a high-risk haplotype for the dystrobrevin binding protein 1 (DTNBP1) gene in the Irish study of high-density schizophrenia families. Mol. Psychiatry 2003, 8:499-510.
54. Viding E., Williamson D.E., Hariri A.R. Developmental imaging genetics: challenges and promises for translational research. Dev. Psychopathol. 2006, 18:877-892.
55. Volk D.W., Austin M.C., Pierri J.N., Sampson A.R., Lewis D.A. Decreased GAD67 mRNA expression in a subset of prefrontal cortical GABA neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 2000, 57:237-245.
56. Weickert C.S., Straub R.E., McClintock B.W., Matsumoto M., Hashimoto R., Hyde T.M., et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch. Gen. Psychiatry 2004, 61:544-555.
57. Williams N.M., Preece A., Morris D.W., Spurlock G., Bray N.J., Stephens M., et al. Identification in 2 independent samples of a novel schizophrenia risk haplotype of the dystrobrevin binding protein gene (DTNBP1). Arch. Gen. Psychiatry 2004, 61:336-344.
58. Williams N.M., O'Donovan M.C., Owen M.J. Is the dysbindin gene (DTNBP1) a susceptibility gene for schizophrenia? Schizophr. Bull. 2005, 31:800-805.
59. Wolf C., Jackson M.C., Kissling C., Thome J., Linden D.E. Dysbindin-1 genotype effects on emotional working memory. Mol. Psychiatry 2011, 16:145-155.
60. Yee C.L., Jones K.R., Finger T.E. Brain-derived neurotrophic factor is present in adult mouse taste cells with synapses. J. Comp. Neurol. 2003, 459:15-24.